DSM - Repurchase of shares (week 23)

* Reuters is not responsible for the content in this press release.

Fri Jun 6, 2008 3:19am EDT

  HEERLEN, NETHERLANDS, Jun 06 (MARKET WIRE) -- 

Royal DSM N.V. has repurchased 769,914 of its own shares in the period from
29 May 2008 up to and including 4 June 2008 at an average price of EUR 39.17.
This is in accordance with the second phase of the share buyback program,
announced on 5 May 2008. The consideration of this repurchase was EUR 30.2
million.

    The total number of shares repurchased under the second phase of this
program
to date is 2,790,496 shares for a total consideration of EUR 103.9 million.

    DSM - the Life Sciences and Materials Sciences Company

    Royal DSM N.V. creates innovative products and services in Life Sciences and
Materials Sciences that contribute to the quality of life. DSM's products
and services are used globally in a wide range of markets and applications,
supporting a healthier, more sustainable and more enjoyable way of life. End
markets
include human and animal nutrition and health, personal care, pharmaceuticals,
automotive,coatings and paint, electrics and electronics, life protection and
housing.
DSM has annual sales of almost EUR 8.8 billion and employs some 23,000 people
worldwide. The company is headquartered in the Netherlands, with locations on
five continents. DSM is listed on Euronext Amsterdam. More information:
www.dsm.com.


For more information:

DSM Corporate Communications          DSM Investor Relations
Elvira Luykx                          Hans Vossen
tel. +31 (0) 45                       tel. +31 (0) 45 5782864
5782035                               fax +31 (0) 45 5782595
fax +31 (0) 45                        e-mail
5740680                               investor.relations@dsm.com
e-mail media.relations@dsm.com

    
Press release-pdf: http://hugin.info/130663/R/1225497/259119.pdf

    Copyright Copyright Hugin AS 2008. All rights reserved.

    



Copyright 2008, Market Wire, All rights reserved.

-0-
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.